Trade Secret Status Triggers Marketing Exclusivity For Chinese Drug Manufacturer
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - A traditional medicine used to treat osteoporosis has been declared a technological secret by the Chinese government, providing the Tongjitang Chinese Medicine Company with five years of marketing exclusivity under State Food and Drug Administration rules
You may also be interested in...
First NYSE-listed TCM Firm Faces Buyout
SHANGHAI - Tongjitang Chinese Medicine Company has received a proposal letter for the acquisition of all the company's outstanding ordinary shares, which would make it a private company, the Shenzhen-based company announced on March 10
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).